异麦芽糖酐铁在肿瘤相关性贫血治疗中的研究进展  

Research progress in the treatment of cancer-related anemia with iron isomaltoside

作　　者：李俊丽 邓涓 盛赠美 Li Junli;Deng Juan;Sheng Zengmei(Changsha Hospital Affiliated to Hunan University of Traditional Chinese Medicine,Changsha 410208,China;The Third Hospital of Changsha City,Changsha 410015,China)

机构地区：[1]湖南中医药大学附属长沙医院,湖南长沙410208 [2]长沙市第三医院,湖南长沙410015

出　　处：《实用药物与临床》2025年第4期294-299,共6页Practical Pharmacy and Clinical Remedies

基　　金：白求恩公益基金会项目(ffbt-B-2022-008)。

摘　　要：肿瘤相关性贫血(Cancer-related anemia,CRA)是指肿瘤患者在肿瘤发展及治疗过程中发生的贫血,是恶性肿瘤的常见并发症之一,对患者生存、疾病进展、治疗效果及生存质量具有重要影响。CRA最常见的治疗方法包括输血、促红细胞生成刺激剂(Erythropoiesis stimulating agent,ESA)和铁疗法。由于血源的紧张以及ESA治疗存在血栓栓塞风险,需要寻找到输血和ESA治疗的合理替代方案。异麦芽糖酐铁作为新上市的第3代静脉铁剂,能缓解癌症患者贫血,减少输血需求和血栓栓塞事件,未来可能在CRA的治疗中具有重要作用。本文综述了异麦芽糖酐铁在CRA患者中的治疗进展,评估异麦芽糖酐铁改善CRA患者贫血、提高生活质量和减少输血需求的可行性。Cancer-related anemia(CRA)mainly refers to anemia that occurs in tumor patients during tumor development and treatment,and is one of the common complications of malignant tumors,which has an important impact on patient survival,disease progression,therapeutic efficacy,and quality of life.Currently,the most common treatments for CRA include blood transfusion,erythropoiesis-stimulating agent(ESA)and iron therapy.Due to the strain on the blood supply and the thromboembolic events associated with ESA therapy for CRA,there is a need for rational alternatives to blood transfusion and ESA therapy.Iron isomaltoside,a newly available third-generation intravenous iron agent,alleviates anemia in cancer patients and reduces the need for blood transfusions and thromboembolic events,which may play an important role in the treatment of CRA in the future.The purpose of this article is to discuss the therapeutic advances of iron isomaltoside for patients with CRA and to assess the feasibility of iron isomaltoside in improving anemia,increasing quality of life,and reducing the need for blood transfusions in patients with CRA.

关 键 词：肿瘤相关性贫血 异麦芽糖酐铁 生活质量 铁剂 输血 促红细胞生成刺激剂 

分 类 号：R730.5[医药卫生—肿瘤]